Skip to main content
TipRanks
Go Ultimate75% OFF

Recursion Pharmaceuticals (RXRX) AI Stock Analysis

4,728 Followers
RXRX

Recursion Pharmaceuticals

(NASDAQ:RXRX)

Select Model
Rating:54Neutral
Price Target:$3.00â–²(10.29% Upside)
Action:reiterated
Date:11/04/26

RXRX scores as a balanced but higher-risk biotech: strong earnings-call momentum (pipeline progress, partnership inflows, extended runway, and reduced expense guidance) is offset by very weak profitability and significant ongoing cash burn in the financials. Technical signals are neutral-to-slightly weak, and valuation is difficult to support on a negative P/E with no dividend yield provided.

Positive Factors
AI Platform ScaleThe large proprietary dataset and closed-loop connection between biology, chemistry, and clinical development can strengthen Recursion’s discovery engine over time. Scale may improve target selection, molecule design, and learning efficiency, creating a durable platform advantage as more programs generate data.
Negative Factors
Cash BurnDeeply negative operating and free cash flow shows that the current business does not yet fund its operations internally. Continued investment in discovery and clinical development therefore requires substantial external or partner capital, increasing financing dependence and execution pressure.

Recursion Pharmaceuticals Key Performance Indicators (KPIs)

Revenue by SegmentBreaks down revenue by different business units or product lines, highlighting which areas are driving growth and which may need strategic adjustments. This insight helps assess the company's diversification and dependency on specific segments.

-$10.00M$0.00$10.00M$20.00M$30.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Operating revenue is highly lumpy and dominates total revenue, reflecting milestone and collaboration cash recognition rather than recurring product sales; grant revenue is immaterial and episodic. Management’s disclosure of >$500M in realized partnership inflows (including >$260M from Roche‑Genentech) and ongoing milestone opportunities explains recent spikes and supports the cash runway, but also makes top‑line growth timing‑dependent. For investors, prioritize the cadence of partnership milestones and clinical/IND triggers that unlock payments, and watch execution/timing risk rather than quarter‑to‑quarter revenue volatility.

Data provided by:The Fly

Recursion Pharmaceuticals (RXRX) vs. SPDR S&P 500 ETF (SPY)

-40%-30%-20%-10%0%10%20%30%RXRX-34.77%SPY+13.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.69B
Dividend Yield
―
Average Volume (3M)
23.66M
Price to Earnings (P/E)
-3.0
Beta (1Y)
3.09
Revenue Growth
56.18%
EPS Growth
50.69%
Country
US
Employees
600
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Recursion Pharmaceuticals Business Overview & Revenue Model

Company Description

Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines te...

How the Company Makes Money

Recursion primarily makes money through (1) collaboration and partnership revenue with pharmaceutical partners and (2) its own drug discovery and development pipeline, with potential future revenues from product sales if its candidates are approved....

Recursion Pharmaceuticals Earnings Call Summary

Earnings Call Date:Nov 02, 2026(Q3-2026)|% Change Since:-28.98%|Next Earnings Date:Mar 03, 2027
Earnings Call SentimentPositive

The call was strongly positive, led by encouraging early clinical activity for REC-4881 and REC-1245, progress across Sanofi, Roche, and Genentech partnerships, more than $535 million in partner cash inflows, substantial platform productivity gains, a $200 million financing, and runway into 2029. The main negatives were treatment-related adverse events, dose-limiting toxicities at higher REC-1245 doses, the early and investigational nature of the clinical data, and the need for further regulatory and registrational validation. Highlights significantly outweighed the lowlights.

Positive Updates

Positive Clinical Data for REC-4881 in FAP
In the TUPELO study, 13 of 15 evaluable patients, or 87%, had a reduction in total polyp burden after 12 weeks of treatment. About one in three patients had a greater than or equal to 65% reduction in total polyp burden in 12 weeks.

Negative Updates

REC-4881 Treatment-Related Adverse Events and Discontinuations
At 4 milligrams once daily, 21 of 26 safety-evaluable patients, or about 81%, had Grade 1 or 2 treatment-related side effects. Four patients had Grade 3 treatment-related events, including two skin reactions and two CPK elevations. Four patients discontinued treatment because of Grade 1 or 2 events; two discontinuations involved preexisting conditions, while the others involved Grade 1 diarrhea and Grade 2 rash.

Company Guidance

Recursion expects cash runway to extend into 2029; 2026 full-year cash operating expense guidance is less than $375 million, excluding partnership inflows and one-time expenses, and in 2027 cash operating expenses are expected to be less than $360 million. Sanofi’s optioned candidate is expected to begin phase I in 2027, with potential for additional partner milestones in 2027; for REC-4881, the company is targeting initiation of a registrational study in the second half of 2027, based on regulatory alignment, and expects to update FDA conversations and generate additional phase II data; for REC-1245, preliminary data from the endometrial expansion cohort are expected in the second half of 2027, along with additional clinical readouts from the rest of the portfolio.

Recursion Pharmaceuticals Financial Statement Overview

Summary

Revenue is growing strongly (+24.386% TTM), but profitability and cash generation are very weak (gross margin ~10.7%, EBIT margin ~-703%, negative operating cash flow and free cash flow around -$311M/-$314M TTM). The balance sheet is a relative strength with low leverage (debt-to-equity ~0.08), yet persistently deep losses and lumpy, milestone-driven revenue increase dilution and execution risk.

Income Statement

24Negative

Balance Sheet

63Positive

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue68.23M74.68M58.84M43.88M39.68M10.00M
Gross Profit7.33M-46.27M13.60M1.29M-8.59M10.00M
EBITDA-405.71M-559.38M-426.72M-307.63M-227.66M-175.12M
Net Income-475.67M-644.76M-463.66M-328.07M-239.48M-186.48M
Balance Sheet
Total Assets1.22B1.47B1.45B653.70M701.29M610.35M
Cash, Cash Equivalents and Short-Term Investments549.85M743.29M594.35M391.56M549.91M516.56M
Total Debt74.70M77.97M108.49M50.67M51.01M11.48M
Total Liabilities315.90M343.26M413.82M190.26M215.48M67.41M
Stockholders Equity905.81M1.13B1.03B463.44M485.81M542.94M
Cash Flow
Free Cash Flow-314.48M-378.28M-372.87M-299.74M-120.88M-198.41M
Operating Cash Flow-310.53M-371.81M-359.17M-287.78M-83.52M-158.61M
Investing Cash Flow-3.95M-16.87M260.06M-10.23M193.25M-271.74M
Financing Cash Flow210.41M521.53M304.12M140.13M154.34M458.54M

Recursion Pharmaceuticals Technical Analysis

Technical Analysis SentimentNegative
Last Price2.72

Price Trends

50DMA3.75Negative
100DMA3.54Negative
200DMA3.46Negative

Market Momentum

MACD-0.21Positive
RSI33.32Neutral
STOCH7.10Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RXRX, the sentiment is Negative. The current price of 2.72 is below the 20-day moving average (MA) of 3.64, below the 50-day MA of 3.75, and below the 200-day MA of 3.46, indicating a bearish trend. The MACD of -0.21 indicates Positive momentum. The RSI at 33.32 is Neutral, neither overbought nor oversold. The STOCH value of 7.10 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RXRX.

Recursion Pharmaceuticals Risk Analysis

Recursion Pharmaceuticals disclosed 107 risk factors in its most recent earnings report. Recursion Pharmaceuticals reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.We may acquire additional businesses, products, form strategic alliances, or create joint ventures and we may not realize the benefits of such transactions.Q4, 2025
2.If we achieve success in our clinical trials, we would need to scale our operations to support commercialization, and we may encounter difficulties in managing this growth.Q4, 2025
3.Increasing scrutiny and changing expectations from governments, regulators, and third-parties relating to environmental, social and governance (ESG) policies and practices may cause us to incur additional costs, expose us to additional risks or impact our reputation.Q4, 2025

Recursion Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

RXRX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
NRIXNRIX61Neutral$1.56B5.6749.34%―738.76%―
RXRXRXRX54Neutral$1.70B-2.99-47.85%―56.18%50.69%
DNLIDNLI54Neutral$2.89B-10.29-33.98%――40.59%
GLUEGLUE54Neutral$775.03M-5.28-30.14%―-61.26%-597.59%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ABSIABSI50Neutral$1.31B-9.50-60.84%―-47.18%12.12%
GENBGENB42Neutral$1.27B-4.15-146.07%―――

* Healthcare Sector Average

Performance Comparison

0%100%200%300%RXRXDNLINRIXGLUEABSIGENBDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
RXRX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
RXRXRecursion Pharmaceuticals, Inc2.72-1.13-29.35%
DNLIDenali Therapeutics18.000.844.90%
NRIXNurix Therapeutics, Inc.14.24-1.09-7.11%
GLUEMonte Rosa Therapeutics, Inc.9.07-4.45-32.91%
ABSIAbsci Corp.7.584.81173.65%
GENBGenerate Biomedicines, Inc.9.84-2.81-22.21%

Recursion Pharmaceuticals Corporate Events

Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresProduct-Related Announcements

Recursion Reports Clinical Progress as Sanofi Options First Candidate

Positive
Nov 2, 2026

On November 2, 2026, Recursion, a clinical-stage company pioneering AI-enabled drug discovery and development, reported third-quarter results and clinical updates. Phase 2 data showed REC-4881 produced deep, durable reductions in gastrointestinal pol...

Business Operations and StrategyPrivate Placements and Financing

Recursion Pharmaceuticals prices offering and advances pipeline

Positive
Oct 15, 2026

On Oct. 15, 2026, Recursion Pharmaceuticals moved to strengthen its balance sheet and pipeline by pricing an underwritten public offering of 61.54 million Class A shares at $3.25, for expected gross proceeds of about $200 million before fees. All sha...

Business Operations and StrategyProduct-Related Announcements

Recursion, Tempus Expand AI and RNA Collaboration Agreements

Positive
Sep 21, 2026

On September 15, 2026, Recursion Pharmaceuticals amended its long-term data and AI collaboration with Tempus AI, extending the master agreement term from five to six years and waiving its prior right to terminate for convenience. The amendment lowers...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026